Orencia (J0129) cost and reimbursement per infusion

$45.937 per 10 mg ($4.5937/mg) is Part B's ASP+6% rate for Q4 2026. At the 750 mg band (60 to 100 kg, the worked example on this page) the drug alone runs $3,445.27, and the patient's 20% coinsurance on the full claim is $702.48 once the $283 Part B deductible is met, with no annual out-of-pocket maximum to cap it. Full explanation: How Medicare Part B drug cost sharing works →

Medicare pays J0129 per 10 mg billing unit, not per vial or per dose. A 750 mg dose is 75 billing units — divide the ordered mg by 10, not by the 250 mg vial size.

What the induction schedule and the other bands cost

Each band uses whole 250 mg vials with nothing discarded: two for 500 mg, three for 750 mg, four for 1,000 mg, all billed JZ. The schedule is the same at every band — weeks 0, 2 and 4, then every 4 weeks — so the first year runs 14 infusions (three induction doses plus eleven maintenance doses), and every year after that is a 13-dose maintenance year.

At 750 mg, the maintenance-year total is $45,661.40 before the sequester (13 doses at $3,512.41 each). The 20% coinsurance scales with the band: $472.80 total at 500 mg, $702.48 at 750 mg ($689.05 drug plus $13.43 infusion), and $932.17 at 1,000 mg, each once the Part B deductible is met.

For the reference patient — 750 mg, 75 units, drug plus the 96365 administration code — Medicare allows $3,512.41, and the Part B coinsurance on that is $702.48. Plans A, B, C, D, F, G, M and N cover that coinsurance in full, so those patients owe nothing per infusion once the $283 deductible is met. Plans K and L do not, and because Orencia is billed every 4 weeks, most claims in a plan year land after the deductible is already met. The infusion that lands before the deductible is met costs a Plan K patient $605.94; every infusion after it costs $351.24. See what each Medigap plan (A–N) owes on this claim →

Only the letters that leave this patient a balance are listed. The full A–N grid, the high-deductible variants, Plan N’s office-visit carve-out and the MACRA restriction on Plans C and F are at Medigap Plans A–N.

Commercial payers negotiate their own rate for J0129, not ASP+6%. Our corpus holds published rates from 37 of 37 payer files, and Aetna's all-states median is $46.42 per unit (10 mg), putting the 75-unit dose at $3,481.50 before benefits. That rate itself differs by payer and by state, and what the patient ultimately owes comes down to their specific plan benefits. Full explanation: How commercial drug reimbursement works →

These four bill under different units, so the per-unit rates alone don’t say which claim costs more — the dose sets that. They matter here because 28 of the 29 payers in our abatacept corpus require a conventional DMARD such as methotrexate first, and several then name one of these three as a preferred biologic before Orencia is approved. For rheumatoid arthritis, Excellus's policy reads: "treatment with IV Orencia will require failure or serious side effects with of Inflectra/Avsola or Simponi Aria." Independence's reads: "documented failure, contraindication, or intolerance to infliximab (Remicade) or golimumab (Simponi Aria)." No abatacept biosimilar exists.

On a commercial plan, the ORENCIA On Call Copay Program takes the drug cost to $5 per month, up to $15,000 a year, and covers the drug line only — not the 96365 administration or an office visit, which are billed separately. It excludes Medicare, Medicaid, TRICARE, VA and other government program patients. Uninsured patients with financial hardship may qualify for free drug through the BMS Patient Assistance Foundation.

Three foundation funds that once covered abatacept are closed: TotalAssist Rheumatoid Arthritis ($4,000/year), TotalAssist Psoriatic Arthritis ($3,500/year), and HealthWell AutoImmune Medicare Access ($2,800/year). HealthWell's ANCA-associated vasculitis and giant cell arteritis funds, and TotalAssist's ankylosing spondylitis fund, are not Orencia indications and don't apply regardless of status. Patients priced out of the IV claim can move to the subcutaneous 125 mg weekly syringe or ClickJect, a pharmacy-benefit product billed through the drug plan rather than the practice's infusion claim. See every program for this patient, with current status →

Sources: CMS ASP pricing files (Q4 2026); Medicare physician fee schedule (96365, 99214, national non-facility); Medicare Part B deductible (2026); Medicare Rights Center 2026 Medigap plan benefits chart; 37 commercial payer published price files (Q2 2026); ORENCIA On Call Copay Program and BMS Patient Assistance Foundation terms (orencia.com/support-savings, bmspaf.org, verified April 8, 2026).

Reviewed September 21, 2026 by Erin Rose, CareCost Estimate founder. Methodology →